Sophiris Bio (SPHS) Stock Price, News & Analysis

Company Overview

Sophiris Bio is a clinical-stage biopharmaceutical company focused on developing targeted therapies for urological and related conditions. Headquartered in King of Prussia, Pennsylvania, the company leverages proprietary protein engineering to create treatments designed for localized delivery, aiming to minimize systemic side effects and improve patient outcomes.

The company’s lead therapeutic candidate, PRX302 (also known as topsalysin), is an injectable proaerolysin-based therapy designed to selectively destroy prostate tissue in patients with benign prostatic hyperplasia (BPH) and localized prostate cancer. PRX302 has advanced through multiple Phase 2 clinical trials, demonstrating the potential to provide durable symptom relief with a favorable safety profile. In addition, Sophiris Bio is developing PRX124, an intradetrusor injectable therapy intended to address female stress urinary incontinence by selectively targeting and remodeling the urethral sphincter region.

Sophiris Bio’s development programs are supported by ongoing interactions with regulatory authorities in the United States, and the company is preparing for pivotal studies to potentially bring its urology-focused candidates closer to commercialization. By concentrating on high-need areas within men’s and women’s health, Sophiris Bio seeks to establish strategic partnerships and licensing arrangements that can accelerate late-stage development and expand global access to its innovative treatment portfolio.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $4 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SPHS Stock Analysis - Frequently Asked Questions

How were Sophiris Bio's earnings last quarter?

Sophiris Bio, Inc. (OTCMKTS:SPHS) released its quarterly earnings data on Thursday, May, 9th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02.

How do I buy shares of Sophiris Bio?

Shares of SPHS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sophiris Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), (CPXX) (CPXX), SELLAS Life Sciences Group (SLS), Advanced Micro Devices (AMD), Rigel Pharmaceuticals (RIGL) and Anavex Life Sciences (AVXL).

Company Calendar

• Last Earnings: 5/09/2019
• Today: 9/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:SPHS
• CIK: 1563855
• Web: www.sophirisbio.com
• Phone: (858) 777-1760
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 35,550,000
• Free Float: N/A
• Market Cap: $4 thousand
• Optionable: Not Optionable
• Beta: 1.94